bexarotene + cisplatin + vinorelbine

The combination of bexarotene, cisplatin, and vinorelbine is a treatment regimen that has been studied for non-small-cell lung cancer (NSCLC). This combination was evaluated in clinical trials to determine whether adding bexarotene to standard cisplatin/vinorelbine chemotherapy could provide additional survival benefits for patients with advanced NSCLC. ## Clinical Trials and Efficacy A randomized Phase III trial was conducted to assess the efficacy of this combination. The study evaluated whether adding bexarotene to first-line cisplatin/vinorelbine therapy would improve survival outcomes in patients with advanced NSCLC[1][2]. The trial enrolled 623 patients (312 in the control group receiving only cisplatin/vinorelbine and 311 in the experimental group receiving bexarotene plus cisplatin/vinorelbine)[1]. Overall, the study found that the addition of bexarotene to first-line chemotherapy did not increase survival in the general population of patients with advanced NSCLC[1]. However, an unplanned retrospective analysis revealed that a subgroup of bexarotene-treated patients (approximately 32% or 98 of 306 patients) who developed high-grade hypertriglyceridemia appeared to have better survival (12.3 months versus 9.9 months in the control group)[1]. This suggests that triglyceride response may potentially serve as a biomarker for identifying patients who might benefit from bexarotene treatment. ## Components of the Combination ### Bexarotene Bexarotene is a synthetic rexinoid that selectively activates retinoid X receptors (RXRs)[5][7]. It is FDA-approved for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy[4][6][8]. Bexarotene works by interfering with the growth of cancer cells through modulation of cell growth, apoptosis, and differentiation[7]. ### Cisplatin and Vinorelbine Cisplatin and vinorelbine are established chemotherapy agents commonly used in combination for the treatment of NSCLC. This combination serves as a standard first-line chemotherapy regimen for advanced NSCLC. ## Side Effects The incidence, type, and severity of grade 3/4 adverse events were generally comparable between the cisplatin/vinorelbine arm and the cisplatin/vinorelbine/bexarotene arm, with some exceptions[1]. Leukopenia was more common in the chemotherapy-only arm, while hyperlipemia, hypothyroidism, dyspnea, and headache were more frequent in the chemotherapy/bexarotene arm[1]. This combination represents an investigational approach that, while not showing overall survival benefit in the general NSCLC population, may potentially benefit specific patient subgroups identified by biomarkers such as hypertriglyceridemia response.